A RANDOMISED, PROSPECTIVE PARALLEL AND OPEN LABEL STUDY TO COMPARE EFFICACY AND SAFTY OF SYNBIOTICES WITH TOCOTRIENOL IN NON ALCHOLIC FATTY LIVER DISEASE
Main Article Content
Keywords
Non-alcoholic fatty liver disease, Synbiotics, Tocotrienol, LFT, Ultrasonography
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) covers spectrum of clinical entities ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) to cirrhosis. Its incidence is rising worldwide, seriously endangering human health, and its pathogenesis is still unclear. Increasing evidence has shown that intestinal flora plays an important role in the occurrence and development of NAFLD.
Aims and objectives: To compare the effectiveness of synbiotics and tocotrienol in NAFLD patients and to evaluate the safety and compliance of synbiotic and tocotrienol.
Materials & Methods: 60 patients of NAFLD attending the OPD and IPD of a tertiary care hospital. Group A was prescribed: Tocotrienol: 200 mg Twice a day and Group B was prescribed: Synbiotic - 5 Billion Colony Forming Units (BCFU) Twice a day. Liver Function Test and Ultrasound was done and compared on day 0,30,60 and 90.
Results: The mean age of NAFLD patient was 43.030±10.561 years in group A and 45.567±11.312 years in group B. Mean change in ALP (p= 0.930), GGT (p=0.132), direct bilirubin (p= 0.103) and total proteins (p= 0.564) remained statistically non-significant in both groups over 90 days of treatment. In both groups, mean change (decrease) in ALT from baseline became statistically significant (p=0.001) at 30 days and highly significant (p=0.0001) at 90 days 33% change is observed in USG scoring in Group B, 20% in Group A over 90 days of treatment.
Conclusion: Group B is more efficacious than group A which is shown by improvement in ultrasound grading, with statistical significant decrease in AST in group B and non significant changes in ALP, GGT between groups A and group B. However Group A drug is better tolerated than Group B.
References
2. Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
4. Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids. 2010;82:265–71.
5. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–64.
6. Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–1153
7. Malaguarnera M, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545–53.
8. Hadi A, et al. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Crit Rev Food Sci Nutr. 2018:1–12.
9. Mofidi F, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662–668.
10. Eslamparast T, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535–42.
11. Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–9.
12. Betrapally NS, et al. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? Gastroenterology. 2016;150:1745–1755.:e3
13. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on humanhealth. Nutrients. (2017) 9:1021.
14. Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease. Front Microbiol. (2018) 9:61.
15. Maya Balakrishnan, Parth Patel, Sydney Dunn-Valadez, Cecilia Dao, Fasiha Kanwal et,al.Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis,Clinical Gastroenterology and Hepatology, Volume 19, Issue 1,2021,Pages 61-71.
16. Li, F., Xu, B., Soltanieh, S., Zanghelini, F., Abu-Zaid, A., & Sun, J. (2021). The effects of tocotrienols intake on obesity, blood pressure, inflammation, liver and glucose biomarkers: a meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition, 62(26), 7154–7167.
17. Pervez MA, Khan DA, Ijaz A, Khan S. Effects of Delta-tocotrienol Supplementation on liver Enzymes, Inflammation, Oxidative stress and hepatic steatosis in Patients with Nonalcoholic Fatty Liver Disease.Turk J Gastroenterol. 2018;29(2):170-176.
18. Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW. Tocotrienols for normalization of hepatic echogenic response in nonalcoholic fatty liver: a radomised placebo-controlled clinical trial. Nutr J. 2013;12(1): 166
19. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535-42.
20. Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of synbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial. Int J Prev Med. 2016;10;(7):77-9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Khushbakht Kaur Dhaliwal
Post Graduation, Jr 3 Pharmacology, Baba Farid University Of Health Sciences
Dr Gurpreet Kaur Randhawa
Head Of Department, Pharmacology
Dr Ajay Chhabra
Head Of Department, Medicine